CALL FOR PROPOSALS

The Stony Brook Cancer Center (SBCC) is pleased to announce a pilot funding opportunity for Investigator Initiated Trials in Oncology

Rolling Call for Proposals

Proposals should be submitted to Joann.Delucia-Conlon@stonybrookmedicine.edu

REQUEST FOR PROPOSALS (RFP): $20,000 per year renewable for up to 2 years with documented progress (total funding = $40,000 per funded proposal)

The purpose of this RFP is to provide start-up funds for investigator initiated clinical trials (IITs) with a therapeutic intent to be performed at SBCC. Impactful and successful IITs are considered necessary for NCI cancer center designation. IITs build upon the strengths of cancer center programs in basic or translational research and that showcase collaborations across departments and disciplines are most desirable. While all IITs are encouraged, this RFA is specifically designated to support clinical trials with a therapeutic intent. Translational projects with laboratory or imaging correlates are encouraged; however, all proposals must include a clinical trial with patient accrual in the design. Priority will be given to projects believed to have a high probability of external funding in the future or that address an unmet need in cancer care. Priority will also be given to proposals that foster collaboration between basic scientists and clinical investigators in cancer center programs. Early career investigators are encouraged to apply.

DEADLINE: Rolling Deadline

Format for Application

A complete application must include the following, in a single PDF file. If any requested information is not included at the time of submission, the proposal will not be reviewed.

1. Abstract of the proposal - 1 paragraph
2. Body of proposal - 3 pages maximum
   - Abbreviated Background: Provide the rationale for the proposed study
   - Study Hypothesis
   - Specific Aims and Objectives
   - Experimental Approach with a brief Statistical Plan and Sample Size Justification
   - Clinical Trial accrual expectations
   - Clinical Relevance and Feasibility: Specifically address the relevance of the clinical trial to oncologic practice and discuss achievability for patient accrual to complete the aims of the trial in the allotted time frame
3. Description of how the pilot funds will be used toward securing extramural research funding to include target funder and timeline for submission.

4. Key References - 1 page maximum
   - Review literature relevant to the project.

5. Budget (funding period is 2 years)
   - Funding is available for salaries and benefits of students, technicians, and other non-faculty project personnel, technical supplies, lab supplies, equipment, and miscellaneous expenses.
   - This budget does not require overhead but does require employee benefits at the same rate as extramural proposals.
   - Grant funds cannot be used for travel that is not directly related to the research proposed in the project, and any travel must be pre-approved by the Associate Director of Administration for the Cancer Center.
   - Funds cannot be used to support faculty travel or attendance at conferences, outside consultants, or office equipment, including computers.
   - PI may transfer up to 25% of the award into different categories of spending without written permission, as long as the category is in the original budget approved by the Associate Director of Administration for the Cancer Center.
   - Statistical support is provided by the cancer center statistician or by voucher for statistics core.
   - The Cancer Center will also provide the necessary CTO support for each funded clinical trial.

6. NIH Biographical Sketch
   - Complete for each Principal Investigator and co-Investigator.

7. A Letter of Support from the Disease Management Team Leader is strongly encouraged. If the topic is not applicable to a specific DMT, the department chair or division chief may provide the Letter of Support. This letter will be reviewed by panel members and at a minimum, should include assurances that the DMT or the department/division:
   - fully supports the proposed clinical trial
   - feels the trial addresses an important or timely clinical question
   - agrees that the clinical trial can be successfully accomplished as written
   - accrual goals are feasible in the 2 year time frame